Impact of cluster of differentiation 20 expression and rituximab therapy in classical Hodgkin lymphoma: Real world experience

The prognostic impact of CD20 expression and rituximab therapy in classical Hodgkin lymphoma (cHL) is unclear. Among 310 patients, CD20 was expressed in 66 (22%) cases. The 3-year PFS was 75.1% for CD20(+)and 70% for CD20(−) (p = 0.36). The 3-year PFS was 84.7% for the rituximab group and 67.8% for...

Descripción completa

Detalles Bibliográficos
Autores principales: Abuelgasim, Khadega A., Shammari, Raed Al, Alshieban, Saeed, Alahmari, Bader, Alzahrani, Mohsen, Alhejazi, Ayman, Alaskar, Ahmed, Damlaj, Moussab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076710/
https://www.ncbi.nlm.nih.gov/pubmed/33936943
http://dx.doi.org/10.1016/j.lrr.2021.100240
_version_ 1783684738842624000
author Abuelgasim, Khadega A.
Shammari, Raed Al
Alshieban, Saeed
Alahmari, Bader
Alzahrani, Mohsen
Alhejazi, Ayman
Alaskar, Ahmed
Damlaj, Moussab
author_facet Abuelgasim, Khadega A.
Shammari, Raed Al
Alshieban, Saeed
Alahmari, Bader
Alzahrani, Mohsen
Alhejazi, Ayman
Alaskar, Ahmed
Damlaj, Moussab
author_sort Abuelgasim, Khadega A.
collection PubMed
description The prognostic impact of CD20 expression and rituximab therapy in classical Hodgkin lymphoma (cHL) is unclear. Among 310 patients, CD20 was expressed in 66 (22%) cases. The 3-year PFS was 75.1% for CD20(+)and 70% for CD20(−) (p = 0.36). The 3-year PFS was 84.7% for the rituximab group and 67.8% for the no rituximab group (p = 0.23). Only constitutional symptoms and positive interim PET/CT were significantly associated with worse outcome, HR 3.2 (1.14–9.01; p = 0.028) and 4.3 (2.27–8.1; p < 0.0001), respectively. Neither CD20 expression nor rituximab use significantly impacted outcome.
format Online
Article
Text
id pubmed-8076710
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-80767102021-04-29 Impact of cluster of differentiation 20 expression and rituximab therapy in classical Hodgkin lymphoma: Real world experience Abuelgasim, Khadega A. Shammari, Raed Al Alshieban, Saeed Alahmari, Bader Alzahrani, Mohsen Alhejazi, Ayman Alaskar, Ahmed Damlaj, Moussab Leuk Res Rep Article The prognostic impact of CD20 expression and rituximab therapy in classical Hodgkin lymphoma (cHL) is unclear. Among 310 patients, CD20 was expressed in 66 (22%) cases. The 3-year PFS was 75.1% for CD20(+)and 70% for CD20(−) (p = 0.36). The 3-year PFS was 84.7% for the rituximab group and 67.8% for the no rituximab group (p = 0.23). Only constitutional symptoms and positive interim PET/CT were significantly associated with worse outcome, HR 3.2 (1.14–9.01; p = 0.028) and 4.3 (2.27–8.1; p < 0.0001), respectively. Neither CD20 expression nor rituximab use significantly impacted outcome. Elsevier 2021-04-08 /pmc/articles/PMC8076710/ /pubmed/33936943 http://dx.doi.org/10.1016/j.lrr.2021.100240 Text en © 2021 The Author(s). Published by Elsevier Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Abuelgasim, Khadega A.
Shammari, Raed Al
Alshieban, Saeed
Alahmari, Bader
Alzahrani, Mohsen
Alhejazi, Ayman
Alaskar, Ahmed
Damlaj, Moussab
Impact of cluster of differentiation 20 expression and rituximab therapy in classical Hodgkin lymphoma: Real world experience
title Impact of cluster of differentiation 20 expression and rituximab therapy in classical Hodgkin lymphoma: Real world experience
title_full Impact of cluster of differentiation 20 expression and rituximab therapy in classical Hodgkin lymphoma: Real world experience
title_fullStr Impact of cluster of differentiation 20 expression and rituximab therapy in classical Hodgkin lymphoma: Real world experience
title_full_unstemmed Impact of cluster of differentiation 20 expression and rituximab therapy in classical Hodgkin lymphoma: Real world experience
title_short Impact of cluster of differentiation 20 expression and rituximab therapy in classical Hodgkin lymphoma: Real world experience
title_sort impact of cluster of differentiation 20 expression and rituximab therapy in classical hodgkin lymphoma: real world experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076710/
https://www.ncbi.nlm.nih.gov/pubmed/33936943
http://dx.doi.org/10.1016/j.lrr.2021.100240
work_keys_str_mv AT abuelgasimkhadegaa impactofclusterofdifferentiation20expressionandrituximabtherapyinclassicalhodgkinlymphomarealworldexperience
AT shammariraedal impactofclusterofdifferentiation20expressionandrituximabtherapyinclassicalhodgkinlymphomarealworldexperience
AT alshiebansaeed impactofclusterofdifferentiation20expressionandrituximabtherapyinclassicalhodgkinlymphomarealworldexperience
AT alahmaribader impactofclusterofdifferentiation20expressionandrituximabtherapyinclassicalhodgkinlymphomarealworldexperience
AT alzahranimohsen impactofclusterofdifferentiation20expressionandrituximabtherapyinclassicalhodgkinlymphomarealworldexperience
AT alhejaziayman impactofclusterofdifferentiation20expressionandrituximabtherapyinclassicalhodgkinlymphomarealworldexperience
AT alaskarahmed impactofclusterofdifferentiation20expressionandrituximabtherapyinclassicalhodgkinlymphomarealworldexperience
AT damlajmoussab impactofclusterofdifferentiation20expressionandrituximabtherapyinclassicalhodgkinlymphomarealworldexperience

Ejemplares similares